• Patient must be 21 years or older
• Patient with histopathologically confirmed metastatic breast, pancreatic, or non-small cell lung cancer in stages II-early stage IV.
• Patients must have a life expectancy of over 12 weeks.
• Patient must have a neoplastic lesion definable by diagnostic means, or be capable of providing objective means of measurement of disease progression.
• Patient must have a peripheral white cell count of at least 2400 cells per cubic millimeter of blood and neutrophil count of at least 2000 cells per cubic millimeter.
• Patient must have a platelet count of at least 100,000 per cubic millimeter of blood.
• Patient must have adequate renal and hepatic function.
• Patient must not have had a prior anticancer therapy within 3 weeks, nor any ongoing toxicity associated with prior anticancer therapy.
• Patient must not have concurrent anti-hormonal or corticosteroids therapy.
• Patient must not have significant pleural effusion.
In April 2010, Dr. Matsumura and his colleagues at the ALIN Foundation announced an historic achievement: all cancer patients treated with the SEF Chemo® in 2006 not only went into remission, but remained cancer-free without the toxic side effects normally associated with chemotherapy.
(my highlighting. There is no peer-reviewed data to support this claim)
The results on patients undergoing SEF Chemo® are nothing short of stunning.
(Again, no data to corroborate this marketing statement).
One oncologist, who regularly refers patients to us, remarked that he knows of no other place in the world where achievements such as ours are being accomplished.
Results are still early, (but they have been doing this since 2006) but we are getting response on virtually every patient we treat, as compared to the 20-30% response rates of conventional chemotherapy on the types of cancers we are treating. If we begin treatment while the volume of cancer cells in a patient is still limited (as opposed to advanced late stage IV), we are achieving clinical remissions consistently. By clinical remission we mean that when we use imaging studies with x-rays, MRIs, or ultrasound we cannot find any trace of cancer.
Dr. Matsumura recently announced an 8-week SEF Chemo® treatment that is an alternative to conventional adjuvant chemo-radiotherapy. After this announcement, many early-stage breast cancer patients, who have refused conventional therapies, approached our clinics. We recently treated a nurse with stage I breast cancer with SEF Chemo® because she did not like what she read about either the radiotherapy or chemotherapy for her situation. She underwent 8-cycles of our therapy with no side effects and kept all her hair.
Even with patients who respond quickly, it is our practice that patients undergo a minimum of 8 cycles of therapy to reduce the possibility of reocurrence.
Furthermore, lung cancer patients with today’s conventional chemotherapy eventually succumb within a year. In an effort to explore the broad spectrum of efficacy of SEF Chemo®, the treatment of more and more types of cancer have been undertaken. SEF Chemo® has also been proven successful with non-small cell lung, pancreatic, colon, bladder, liver, cervical, and prostate cancers, which comprise substantially most of the cancers that plague human kind today. SEF Chemo® continues to deliver stunning results.
This new therapy appears to be consistently reliable and far superior to today’s conventional treatments. Only time will tell if our long-term remissions will turn into cures.”